Today: 9 June 2026
Browse Category

NYSE:ZETA 4 November 2025 - 1 June 2026

Zeta Global Stock Pops Before the Bell as AI-Marketing Trade Gets Another Look

Zeta Global Stock Pops Before the Bell as AI-Marketing Trade Gets Another Look

Zeta Global traded at $24.13 in Monday premarket, up 5.42% after a 13.43% Friday surge on heavy volume. Q1 revenue jumped 50% to $396 million; 2026 guidance midpoint raised to $1.785 billion. OpenAI models now support Athena, Zeta’s AI-driven marketing tool. Analyst targets average $28.31, with BofA at $24. Risks include rapid price gains, competition with Salesforce, Oracle, Adobe, and execution on AI growth.
1 June 2026
···
Zeta Global Pops Again as Traders Eye OpenAI Ad Deal

Zeta Global Pops Again as Traders Eye OpenAI Ad Deal

Zeta Global shares rose 3.4% to $19.85 in premarket trading Tuesday after CEO David Steinberg announced an advertising agreement with OpenAI at a JPMorgan conference. The stock had closed up 11.6% at $19.19 on Monday, trading over 17 million shares. Bank of America reinstated coverage with a Buy rating and $24 target. Zeta recently reported first-quarter revenue up 50% year-over-year to $396 million.
19 May 2026
·
Zeta Global Surges 12% After OpenAI Ad Remarks

Zeta Global Surges 12% After OpenAI Ad Remarks

Zeta Global shares rose 11.6% to $19.19 Monday after CEO David Steinberg said the company reached an agreement to help OpenAI run its advertising. The stock outperformed the broader market, with SPY and QQQ both down. Zeta recently joined Snowflake’s Open Semantic Interchange and reported Q1 revenue up 50% year-over-year. Investors cited strong guidance and increased Athena AI agent usage.
19 May 2026
···
Zeta Global Stock Rises as Snowflake Deal Comes Ahead of Key Vote

Zeta Global Stock Rises as Snowflake Deal Comes Ahead of Key Vote

Zeta Global shares closed at $17.19, up 3.68% Friday, outperforming major indexes after joining Snowflake’s Open Semantic Interchange data initiative. The stock retreated to $17.14 after hours. Zeta will present at the JPM 2026 Global Technology, Media and Communications Conference on Monday. First-quarter revenue jumped 50% to $396 million, prompting a full-year guidance raise.
17 May 2026
···
Zeta Global (ZETA) Stock Rises as AI Push Fuels 50% Revenue Growth, Bigger 2026 Target

Zeta Global (ZETA) Stock Rises as AI Push Fuels 50% Revenue Growth, Bigger 2026 Target

Zeta Global shares rose after the company raised its 2026 revenue outlook and reported a 50% jump in first-quarter sales to $396.3 million, beating consensus. The company cited strong adoption of its Athena AI agent and growth in “super-scaled” customers. Adjusted EBITDA climbed to $66.1 million from $46.7 million. The stock traded at $19.17, up 75 cents in late-morning New York trading.
1 May 2026
··
Zeta Global stock jumps in premarket after OpenAI deal for Athena AI marketing agent

Zeta Global stock jumps in premarket after OpenAI deal for Athena AI marketing agent

Zeta Global shares rose 10.8% to $24.00 in premarket trading Tuesday after announcing a collaboration with OpenAI for its Athena product. The company expanded beta access to two AI-powered apps and said TKO Group Holdings participated in early testing. The stock closed Monday at $21.67, up 8.8%, with 13.6 million shares traded. Athena’s full launch is planned by the end of Q1 2026.
6 January 2026
··
Zeta Global stock slips in premarket after an 8% holiday rally — traders eye whether $20 holds

Zeta Global stock slips in premarket after an 8% holiday rally — traders eye whether $20 holds

Zeta Global shares slipped 0.97% to $20.50 in premarket trading Monday after an 8.3% surge Friday, when the stock traded over 10 million shares and swung between $18.86 and $20.71. Analysts cited options activity and thin year-end liquidity for the volatility. No new corporate news accompanied the move. Investors await Zeta’s CES appearance in January and the next earnings update, tentatively set for late February.
29 December 2025
·
Zeta Global (ZETA) Stock Jumps on Heavy Options Activity as Year-End Trading Turns Choppy — Analyst Targets and What to Watch Next

Zeta Global (ZETA) Stock Jumps on Heavy Options Activity as Year-End Trading Turns Choppy — Analyst Targets and What to Watch Next

Zeta Global Holdings shares jumped 8.32% to $20.70 Friday, closing out a quiet post-holiday session with unusually high volume of 10.19 million shares. Options activity surged, with 26,546 contracts traded, led by the $20 call expiring Jan. 16, 2026. The move came without major news, as analysts cited options-driven dynamics in thin year-end trading. U.S. markets are now closed for the weekend.
28 December 2025
·
Zeta Global Holdings Corp (ZETA) Stock Jumps on Heavy Options Activity — Analyst Targets, Fresh Commentary, and What to Watch Before Monday’s Open

Zeta Global Holdings Corp (ZETA) Stock Jumps on Heavy Options Activity — Analyst Targets, Fresh Commentary, and What to Watch Before Monday’s Open

Zeta Global shares jumped 8% to close at $20.68 Friday, with after-hours trading lifting the price to $20.73. Trading volume surged to 10.1 million shares, more than double the average, as options activity spiked, especially in $20 strike calls. The rally came during a quiet session where major indexes slipped slightly on low volume. No major news headlines accompanied the move.
28 December 2025
Zeta Global Holdings Corp Stock (NYSE: ZETA) Weekend Update: Marigold Deal, Raised Guidance, and Analyst Targets as Wall Street Heads Into Year-End

Zeta Global Holdings Corp Stock (NYSE: ZETA) Weekend Update: Marigold Deal, Raised Guidance, and Analyst Targets as Wall Street Heads Into Year-End

Zeta Global Holdings shares rose about 8.3% to $20.70 in Friday’s light post-holiday session after the company completed its $325 million acquisition of Marigold’s enterprise software business and raised guidance for 2025 and 2026. Trading volume exceeded recent averages. Major U.S. indexes slipped modestly in quiet, low-volume trading near all-time highs. Markets reopen Monday after the holiday schedule.
27 December 2025
·
Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

Zeta Global (ZETA) Stock Today: Marigold Deal, AI-Agent Momentum, and Wall Street Targets as Markets Reopen After Christmas

Zeta Global Holdings traded near $19.12 late Friday morning, little changed after opening at $19.05. The stock showed muted movement as U.S. markets reopened post-Christmas with light volume. Investors continue to weigh Zeta’s recent $325 million Marigold acquisition and raised guidance ahead of CES 2026.
26 December 2025
···
Zeta Global (ZETA) Stock Surges on Dec. 24, 2025: Holiday Trading Spike, Analyst Targets, and the Marigold Growth Story

Zeta Global (ZETA) Stock Surges on Dec. 24, 2025: Holiday Trading Spike, Analyst Targets, and the Marigold Growth Story

Zeta Global shares rose 4.36% to near $19.15 by midday December 24, 2025, in a thinly traded, early-closing session. The move followed a gap-up open and heavy options activity, with investors reacting to the company’s raised 2025–2026 outlook after its $325 million Marigold enterprise acquisition. Major indexes hovered near record highs. No new company headlines were issued during the session.
24 December 2025
··
Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Zeta Global (ZETA) – 17th Straight Beat & Raise Quarter Ignites AI-Cloud Rally – Analysts Eye ~$28 Target (≈+70% Upside)

Zeta (NYSE: ZETA) closed Nov. 4, 2025 at $16.70, down 5.2%, with after-hours trading near $18.06. Q3 revenue rose 26% year-over-year to $337.4 million, with net cash from operations up 68%. The company raised its FY2025 revenue outlook to $1.273–1.276 billion. Analyst consensus rates ZETA a “Strong Buy,” with an average 12-month price target of $28.
4 November 2025
··

Stock Market Today

  • NSE Allocates 10% of Annual CSR Fund to Social Stock Exchange
    June 9, 2026, 10:16 AM EDT. The National Stock Exchange (NSE) will deploy 10% of its annual Corporate Social Responsibility (CSR) corpus through the Social Stock Exchange, signaling trust in this market-based platform designed to connect social enterprises with investors. This move aims to enhance transparency and impact investing by leveraging the exchange's resources to support social causes.

Latest articles

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

Regentis Biomaterials Stock: Tiny RGNT Is Back In Focus Before The Bell

9 June 2026
Regentis Biomaterials shares dipped 2 cents to $1.28 premarket after the company announced European surgeon training for its GelrinC knee implant will begin in Q3, marking a key commercial step but leaving investors waiting for revenue proof as the stock trades far below its $8 IPO price.
IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

IREN Stock Approaches $60 as AI Data-Center Bet Hits Key Point

9 June 2026
IREN surged 8.9% to $59.19 and was quoted higher premarket after a bitcoin rebound and renewed focus on its pivot to AI cloud infrastructure, but the stock remains exposed to bitcoin swings, heavy spending, and risks tied to its new 800MW South Australia data center project and major contracts with Nvidia and Microsoft.
AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

AT&T Moves Higher Pre-Market on $45 Billion Payout Plan Still in Focus

9 June 2026
AT&T shares edged up to $22.58 pre-market after reaffirming 2026 guidance and a $45B+ shareholder return plan, providing a cash-flow marker as satellite broadband competition looms; the stock remains pressured by SpaceX risks flagged by Oppenheimer, with second-quarter free cash flow seen at $4.0–$4.5B.
GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

GSK’s $10.6 Billion Oncology Leap Goes Deeper Than Headlines Show

9 June 2026
GSK will buy Nuvalent for $10.6 billion in cash, paying a 40% premium, to boost its oncology pipeline ahead of looming HIV drug patent expiries; Nuvalent shares jumped 38.9% premarket while GSK fell 1.4%, with the deal expected to add to GSK sales and profit from 2027 but dilute earnings per share 2026-2028 if it closes in Q3, and final outcome depends on FDA approvals and regulatory clearance.
Go toTop